We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

c-MET

c-MET inhibitors act on the receptor tyrosine kinase for hepatocyte growth factor (HGF), also known as scatter factor. MET was first cloned in 1984 as a transforming gene from a chemically transformed human cell line. In 1991 the product of the c-met proto-oncogene was identified as the HGF receptor. HGF binding drives cell scattering, invasion and branching morphogenesis, and MET amplification occurs in several tumor types. Capmatinib and merestinib are MET-focused inhibitors, and tivantinib was first described as an inhibitor that does not compete with adenosine triphosphate. Foretinib and cabozantinib block MET together with vascular endothelial growth factor receptor 2 (VEGFR2). Crizotinib also inhibits anaplastic lymphoma kinase and is listed in the sibling ALK category as well.

1 Item

  • Fosgonimeton
    Cat. No.
    A34300
    CAS No.
    2093305-05-4

    Fosgonimeton

    Synonyms: ATH-1017

    Fosgonimeton is a c-Met agonist known to activate the hepatocyte growth factor receptor. This compound exhibits neuroprotective properties, demonstrating efficacy in models of neuroinflammation induced by LPS as well as in Alzheimer's disease models characterized by amyloid-beta pathology. Its potential applications extend to research aimed at understanding neurodegenerative diseases and therapeutic interventions.

    In stock View Details
    5 mg
    $215.00
    10 mg
    $320.00
    All 5 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...